OncoMatch/Clinical Trials/NCT05011487
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
Is NCT05011487 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Osimertinib and Cisplatin for non-small cell lung cancer.
Treatment: Osimertinib · Cisplatin · Pemetrexed — This is a phase II, single-arm, multi-center study of neoadjuvant osimertinib in combination with chemotherapy for the treatment of patients with resectable EGFR-mutant stage III (N2) non-squamous non-small cell lung cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR ex19del
A tumour which harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations (ie, T790M, G719X, Exon20 insertions, S7681 and L861Q).
Required: EGFR L858R
A tumour which harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations (ie, T790M, G719X, Exon20 insertions, S7681 and L861Q).
Disease stage
Required: Stage IIIA, T3-4N2 IIIB (IASLC Version 8)
Excluded: Stage T4 TUMOURS INFILTRATING THE AORTA, THE OESOPHAGUS AND/OR THE HEART, ANY BULKY N2 DISEASE DEEMED UNRESECTABLE
resectable (Stage IIIA or T3-4N2 IIIB) disease (according to Version 8 of the IASLC Cancer Staging Manual)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer therapy
Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug
Cannot have received: EGFR tyrosine kinase inhibitor
Prior treatment with EGFR-TKI therapy
Cannot have received: radiation therapy
Exception: pre-operative only
Patients who have pre-operative radiotherapy treatment as part of their care plan
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify